O ne in four women experience a symptomatic pelvic floor disorder (PFD) with 17% having moderate to severe urinary incontinence (UI), 9.4% fecal incontinence (FI), and 2.9% pelvic organ prolapse (POP). 1 The prevalence of PFDs is higher among perimenopausal and postmenopausal women 60 years or older with prevalence rates ranging from 39% to 50%. 2 With the aging population, the prevalence of PFDs requiring treatment is expected to increase by 56% by 2050. 2 Because PFDs impair the quality of life of women affected by them, it is imperative to explore novel prevention and treatment options. Estrogen therapy has been investigated as a treatment modality for pelvic floor symptoms as estrogen receptors are present in the bladder, vagina, pelvic floor, and anal sphincter. [3] [4] [5] [6] [7] While oral estrogen worsens UI 8 and use of menopausal hormone therapy may have an effect on increasing FI rates after menopause, 9 other studies reported inconclusive effects of oral and topical estrogen to improve FI symptoms 10, 11 and POP. 12 However, topical estrogen has shown to improve vaginal atrophy, overactive bladder, and UI symptoms in the setting of genitourinary syndrome of menopause. 13 In light of some of the benefits of estrogen, other sources of estrogen-like compounds, such as dietary estrogens, should be investigated as potential modulators of PFDs.
Phytoestrogens, also referred to as plant or dietary estrogens, are biochemically similar to estradiol. They are found in foods such as nuts, flax seed oil, soy products, cereals, breads, and legumes. 14 There are three major classes of phytoestrogens: isoflavones (eg, daidzein and genistein), coumestans (eg, coumestrol), and lignans (eg, enterodiol and enterolactone). 15 Depending on their concentration and bioavailability in foods, phytoestrogens can act as estrogen agonists or antagonists. [16] [17] [18] Phytoestrogens have been explored as an alternative to traditional hormone replacement therapy for treatment of menopausal vasomotor symptoms, and more data are needed regarding risks and benefits. 19 This is especially relevant as the results of the Women Health Initiative study showed an increased rate of venous thromboembolic events (VTEs), heart disease, and breast cancer in postmenopausal women taking oral estrogen and progesterone replacement. [19] [20] [21] Of note, only VTEs were increased in women in the estrogen-only arm of the study. 22 Given the biochemical similarity of phytoestrogens to current oral estrogen replacement (estradiol, estriol, and conjugated estrogen), phytoestrogens may be of use in treating or possibly preventing the development of pelvic floor symptoms and conditions. 19 The objective of this review is to discuss the available literature on phytoestrogens and their potential role in the pathophysiology, association, and possible treatment and prevention of pelvic floor conditions, specifically UI, POP, and FI. Future research directions will also be discussed.
METHODS
Medline/PubMed, Cochrane, Scopus, and EMBASE databases were searched from Medline's date source year of 1966 to October 9, 2017, using combinations of the following key words: phytoestrogen, incontinence, prolapse, pelvic or pelvis, fecal or anal, urine or urinary, isoflavone, lignan, soy, daidzein, genistein, o-desmethylangolensin, o-dma, equol, enterodiol, and enterolactone. The literature search was performed independently by the primary author and a certified research librarian. Resulting abstracts were screened for relevant associations of phytoestrogens and PFDs. The articles of relevant articles, or the abstract if no article was available, were reviewed by the group and included in this review. Inclusion criteria were (1) nondescriptive studies, (2) focus on perimenopausal or postmenopausal women, (3) study of or intervention with a phytoestrogen, and (4) evaluation of some aspect related to UI, pelvic floor support or prolapse, and/or FI. Studies were excluded if neither the abstract nor the article was available in English. After review, there were limited data with wide variability in study content. Therefore, it was not feasible to perform a systematic review or meta-analysis.
RESULTS

Phytoestrogens and UI
The most commonly studied PFD in relationship to phytoestrogen use was UI. Nine published studies spanning 2003 to 2017 evaluated the influence of phytoestrogens on the pathophysiology, symptoms, treatment, and potential prevention of UI (Table 1) . Of ii) Ovx mice for 2 mo (NP, n = 6; MP, n = 6) iii) Ovx mice for 2 mo further treated with and without 2-d estradiol treatment (n = 5 and 6, respectively) iv) 12-mo-old mice undergoing sham surgery and treated with vs without 2-d estradiol treatment (n = 5 and 6, respectively) v) 70-wk-old NP mice raised on a phytoestrogen diet (n = 10) vs phytoestrogen-free diet (n = 10) these, four were animal and in vitro studies and the other five were clinical studies in perimenopausal and postmenopausal women. Table 1 includes specific data from these studies. Due to estrogen receptors located in the bladder, vagina, and pelvic floor and the influence of estrogen in connective tissue metabolism and biosynthesis, estrogen and selective estrogen receptor modulators have been investigated as possible treatment options for stress UI (SUI) particularly with respect to their effects on periurethral tissue. 23 In 2003, an in vitro study from researchers in Poland demonstrated that both estradiol and the phytoestrogen, daidzein, increased pubocervical fascia (PCF) fibroblast proliferation compared with control fibroblasts harvested from perimenopausal women with SUI. 23 The authors concluded that the results of their study support the theoretical use of local estrogen and/or phytoestrogens in an attempt to bulk the periurethral connective tissue in the treatment of female SUI.
Nonhuman primates, such as monkeys, are considered a good animal model to study PFDs because similar to humans, they have the ability to walk upright on two legs and have similar gravitational force vectors directed onto their pelvic floors. 24 In animal models, ovariectomized animals are considered analogous to postmenopausal women. 24 A 2008 study in ovariectomized cynomolgus monkeys showed that through a soy enriched diet, chronic (32-month) phytoestrogen treatment increased bladder detrusor muscle and proximal urethral contractile response to carbachol and electrical field stimulation. Other pharmacological stimulation with phenylephrine and endothelin 1 also resulted in significantly higher contractile response in the proximal urethra. A phytoestrogen diet resulted in a thicker and larger mucosal area in all three segments of the urethra compared with the control group. 24 The authors proposed that further studies be designed for human subjects as these findings may translate to treatment options for UI in postmenopausal women.
A 2010 study in ovariectomized mice demonstrated that dietary estradiol and phytoestrogens (equol, genistein, and puerarin) improved urethral closure pressure compared with a control group, adding to the evidence that estradiol and phytoestrogens could possibly be used as preventative or treatment options for UI in postmenopausal women. 25 In this study, mice were fed either a 3-month diet enriched with estradiol, equol, genistein, or puerarin. Urodynamics performed on the mice showed that bladder and urethral pressures were highest in the estradiol group, followed by puerarin-, equol-, and then genistein-treated animals ( Table 1) . Phytoestrogen and estradiol treatment resulted in consistently higher pressures in the urethra compared with the bladder during the filling period and in the filled status. Bladder pressure often exceeded urethral pressures in controls.
A long-term phytoestrogen diet in rats also mediated agerelated reduced detrusor activity. 26 Similar to the 2008 study in cynomolgus monkeys, a 2011 study in ovariectomized versus sham-operated Wistar rats showed that a soy diet was associated with increased bladder detrusor muscle contractile response in aged (52-week-old) rats. 26 No change in bladder contractile response was seen in the young (12-week-old) rats regardless of the surgery or soy diet. It should be noted that different from menopausal women, ovariectomy in this animal model is associated with decreased circulating progesterone, not estrogen, and should be taken into account when interpreting the data.
From the five clinical studies on phytoestrogens and UI in women, three were cohort studies and two were intervention studies. In the three cohort studies (2 cross-sectional and 1 longitudinal), some evidence linking phytoestrogens to both UI symptoms and possible prevention of symptoms was found. 27 In a cross-sectional, population-based cohort survey using the National Health and Nutrition Examination Survey data, the authors reported that increasing concentrations of urinary lignans (enterodiol and enterolactone) were associated with a decreased likelihood of urgency UI (UUI) (OR = 0.92, 95% CI = 0.85-0.99) in postmenopausal women (n = 1789) ( Table 1) . 28 The authors concluded that lignan phytoestrogens may have a protective association with UI symptoms in postmenopausal women.
In a second cross-sectional population-based household survey of Brazilian women (n = 749), the authors reported that current or previous use of soy products to treat menopausal symptoms was associated with a lower prevalence of UI (0.43, 95% CI = 0.24-0.78). 29 It is unclear whether the study data were controlled for history of both estrogen and phytoestrogen use, which might have affected these findings. No data were available for specific types of UI.
As a subset of the longitudinal Study of Women's Health Across the Nation (SWAN) (n = 1459 perimenopausal women), the SWAN Phytoestrogen Study used study investigators to administer food frequency questionnaires to participants at baseline and subsequently at 5 and 9 years. 27 On an annual self-administered questionnaire, participants reported the frequency and type of UI. Discrete proportional hazards models were used to evaluate whether daily intake of phytoestrogens (4 isoflavones, 4 lignans, and coumestrol) recorded from the visit preceding the first reported symptom of UI was associated with the development of monthly or more frequent UI versus remaining continent. Although neither low nor high levels of reported phytoestrogen intake were associated with development of UI in perimenopausal women, the study investigators recommended that future studies evaluate the influence of serum levels of phytoestrogens and their metabolites on UI.
In addition to the cohort study data, two studies reported efficacy data using phytoestrogen as a treatment for UI. In a small, randomized, cross-over trial comparing the effect of a 12-week soy-rich diet versus an isocaloric soy-free diet with 4-week wash-out period between treatments on urogenital symptoms in Thai women (n = 36), the authors reported that UUI symptoms ( from 0.14[0.35] to 0.25[0.50]) and vaginal dryness ( from 0.61[0.84] to 0.92[0.99]) significantly increased after a 12-week soy-free diet (P < 0.05). However, no symptom changes were observed with a soy-rich diet (P > 0.05). 30 Urogenital bother symptoms were based on a nonvalidated scoring system. Other urogenital variables, including the vaginal health index, vaginal pH, and vaginal cytology did not significantly change. The authors reported good study and diet compliance based on participants' serum isoflavones (daidzein and genistein) levels. Despite a reported significant worsening of UUI and vaginal dryness in the Thai women on a soy-free diet, the authors concluded that a soy-rich diet did not relieve urogenital symptoms. However, key differences at baseline existed with more women having UUI and vaginal dryness in the soy-free intervention group compared with women on the soy-rich diet. In their discussion, the authors stated that a longer treatment period (>12 weeks) could be more efficacious for improving urogenital symptoms.
According to a nonrandomized single-center open-label study published in 2017, Dropsordry™, a compounded mixture containing phytoestrogens, reduced mean urgency score by 24.7%, nocturia by 69.4%, and the use of daily panty liners by 66.3% (all P < 0.05) in Spanish perimenopausal women (n = 82). 31 No significant difference was noted in the reduction of SUI (no data provided). After an 8-week treatment, 96% of women reported satisfaction with treatment and 92% reported improvement in quality of life. Of note, this study did not have a control or comparison group.
Phytoestrogens and POP
Compared with the studies on phytoestrogens and UI, there was a paucity of information on phytoestrogens and POP. From this literature search, we report pathophysiologic data from four in vitro and treatment data from one clinical intervention study ( Table 2) . Much of the data on phytoestrogens and POP were reported by Tomaszewski et al in Poland. 23, [32] [33] [34] In 2009, Tomaszewski et al 32 demonstrated that collagen type I levels in cultured PCF fibroblasts taken from a 56-year-old menopausal woman experiencing SUI and POP increased after exposure to estrogen and the phytoestrogen, daidzein. The same research group also demonstrated that PCF fibroblasts produced more type I collagen when exposed to estriol or daidzen regardless of the type of vaginal prolapse mesh applied. In the presence of monofilament mesh, there was a persistent increase in the peak procollagen type 1 N-terminal propeptide (PINP) concentration with estriol and daidzein, but not with estradiol. 32, 33 Compared with type I collagen, type III collagen only showed a persistent increased production by PCF fibroblasts in cultures containing monofilament mesh stimulated with estriol. Interestingly, the highest total type III collagen production was observed in culture treated with tamoxifen regardless of the type of mesh. 34 Based on their findings of increased type I collagen production by PCF fibroblasts in the setting of estrogens and daidzein, Tomaszewski et al 32, 33 concluded that these findings are an indirect rationale for local estrogen and/or phytoestrogen use for female SUI and/or POP.
In a 2016 in vitro and mice study, Iwanaga et al 35 demonstrated that both an estradiol and a phytoestrogen diet increased expression of oxytocin receptors and had a significant impact on oxytocin receptor expression in the uterosacral ligament (Table 2) . Estrogen receptor α and oxytocin receptors are present in the uterosacral ligament. 35 Oxytocin receptors are involved in tissue regeneration in the body, and estrogen regulates the expression of the oxytocin receptor. 35 These findings further support estrogen and phytoestrogens as potential targets for POP prevention and treatment.
In the one POP treatment study, the phytoestrogen, puerarin, demonstrated therapeutic potential in improving POP symptoms in postmenopausal women. 36 Postmenopausal women with stage II to IV prolapse were divided into two groups, either treated with 0.429-mg/d puerarin versus placebo for 30 days (n = 30 and 22, respectively). At the end of the 30-day treatment period (before surgery), POP symptoms were assessed using a nonvalidated score based on a POP-Q examination (defined as "positive" or "strongly positive" improvement in symptoms if 1+ or 2+ stage improvement was noted compared with baseline, respectively). After 30 days, those who were treated with puerarin had significant improvement of POP compared with controls (positive 57% vs 0%, and strongly positive 35% vs 0%, P < 0.05). The women randomized to puerarin or placebo subsequently underwent surgical management of their prolapse where a tissue sample was collected for immunohistochemical analysis. This study showed that the expression of elastin positive rate (9.8[2.8]% vs 2.8[1.3]%, P < 0.05) and collagen I/III ratio (1.1[0.3] vs 0.5[0.3], P < 0.05) were significantly increased in the puerarin group. Neuropeptide Y, vasoactive intestinal polypeptide, and transforming growth factor β levels were also significantly increased compared with controls (all P < 0.05, individual data not shown).
Phytoestrogens and Fecal Incontinence
No studies were found exploring the role of phytoestrogens on FI pathophysiology, symptoms, treatment, or possible prevention.
DISCUSSION
Systemic and topical estrogen therapy has been investigated for pelvic floor symptoms as estrogen receptors are present in the bladder, vagina, pelvic floor, and anal sphincter. [3] [4] [5] [6] [7] While oral estrogen worsens UI 8 and use of menopausal hormone therapy may have an effect on increasing FI rates after menopause, 9 other studies reported inconclusive effects of oral and topical estrogen to improve FI symptoms 10, 11 and POP. 12 However, topical estrogen has shown to improve vaginal atrophy, overactive bladder, and UI symptoms in the setting of genitourinary syndrome of menopause. 13 The current literature is limited especially to compare the potential effects of traditional estrogen and phytoestrogen on pelvic floor symptoms.
Except for the in vitro studies, all studies evaluated ingested or dietary intake of phytoestrogens. Most currently existing studies reported data on the potential impact of phytoestrogens on the pathophysiologic mechanisms and modulation of PFDs. Limited evidence also existed on the potential role of phytoestrogens in the treatment of PFDs and scare data existed on the role of phytoestrogens in the prevention of PFDs. We did not find any evidence supporting the potential impact of phytoestrogens in the pathophysiology or treatment of FI symptoms. More research regarding pathophysiologic mechanisms, associations with symptoms, and response to treatment, especially for POP and FI, are warranted.
From a pathophysiologic role, based on in vitro and animal studies, phytoestrogens, similar to topical estrogen, seem to increase proliferation of the pubocervical musculoconnective tissue 23, 32 and increase the responsiveness of the bladder detrusor muscle and urethra. [24] [25] [26] From observational and small clinical studies evaluating dietary influences of phytoestrogens in women, less evidence existed regarding improvement in UI symptoms, except for reported improvement in nocturia. 31 Phytoestrogens could theoretically influence POP pathophysiology by increasing type I collagen production in the pubocervical musculoconnective tissue, 32, 33 upregulating oxytocin receptor expression in the uterosacral ligaments 35 resulting in improvement in vaginal connective tissue quality. 36 Because estrogen receptors are present in the anal sphincter and pelvic floor, it would be reasonable to investigate phytoestrogen use for FI. 4, 5 Overall, because of the small number of studies, we have noted that the influence of phytoestrogens on PFDs is still exploratory and not well understood.
With regard to the role of phytoestrogens in treatment and possible prevention of PFDs, future studies should consider collecting more data on the bioavailability and metabolism of phytoestrogens in women, because these biologic modulators could potentially affect treatment response. 37 Other important considerations are the safety profile and understanding possible adverse effects of phytoestrogens. Although oral estrogen is associated with an increased risk of endometrial cancer and VTEs, studies evaluating the use of phytoestrogens as hormone replacement therapy have not demonstrated increased risks of these events. 19 In the past, soy intake was thought to increase breast cancer development, but more recent literature seems to support low to normal intake of phytoestrogens (<100 mg/d) even in breast cancer survivors. 38 
CONCLUSIONS
Current literature on the potential role of phytoestrogens in modulating the pathophysiology, symptom association, treatment, and prevention of PFDs is overall scant. Further research is needed to explore these interesting preliminary data and to ascertain potential risks and benefits of phytoestrogen use for treatment in light of the need for other robust treatment and potential prevention modalities.
